MedGenome and Emmes are proud to launch a strategic partnership to focus on advancing Rare Disease research.
Patients and families with rare diseases are one of the most underserved communities in medicine today. India and South Asia have the world’s largest population of people affected by rare and inherited disease.
The MedGenome – Emmes partnership will combine patients’ genomic, phenotypic and epidemiological data into custom rare disease registries.
This help bring faster and more innovative treatments to patients around the world who are suffering from rare diseases.
For more details contact:
Vice President, Corporate and Business Development at MedGenome
Phone: (416) 452-1656
International Finance Corporation, member of the World Bank Group, is investing USD 16.5 million (around Rs 123 crore) in genetic diagnostics and research company MedGenome to increase access to COVID-19 testing in India.
In a paper published in Nature Communications, scientists from MedGenome India/USA, along with an international team of scientists from institutions in India, USA, South Korea, Chile and Australia reported sequencing and analysis of over 150 gallbladder cancer (GBC) samples.
MedGenome, the leading genetic diagnostics, research and data company focused on expanding access for populations in South Asia and other emerging markets today announced an investment of USD 55m led by LeapFrog Investments, a leading specialist investor in emerging markets. Existing investors Sofina and Sequoia also participated in the round.